BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 25044709)

  • 21. Probing the origins of 17β-hydroxysteroid dehydrogenase type 1 inhibitory activity via QSAR and molecular docking.
    Srungboonmee K; Songtawee N; Monnor T; Prachayasittikul V; Nantasenamat C
    Eur J Med Chem; 2015; 96():231-7. PubMed ID: 25884113
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design and synthesis of bisubstrate inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: overview and perspectives.
    Fournier D; Poirier D; Mazumdar M; Lin SX
    Eur J Med Chem; 2008 Nov; 43(11):2298-306. PubMed ID: 18372081
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bicyclic substituted hydroxyphenylmethanone type inhibitors of 17 β-hydroxysteroid dehydrogenase Type 1 (17 β-HSD1): the role of the bicyclic moiety.
    Oster A; Klein T; Henn C; Werth R; Marchais-Oberwinkler S; Frotscher M; Hartmann RW
    ChemMedChem; 2011 Mar; 6(3):476-87. PubMed ID: 21337522
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of nonsteroidal 17beta-hydroxysteroid dehydrogenase 1 inhibitors by pharmacophore-based screening of virtual compound libraries.
    Schuster D; Nashev LG; Kirchmair J; Laggner C; Wolber G; Langer T; Odermatt A
    J Med Chem; 2008 Jul; 51(14):4188-99. PubMed ID: 18533708
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.
    Allan GM; Lawrence HR; Cornet J; Bubert C; Fischer DS; Vicker N; Smith A; Tutill HJ; Purohit A; Day JM; Mahon MF; Reed MJ; Potter BV
    J Med Chem; 2006 Feb; 49(4):1325-45. PubMed ID: 16480268
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis of substituted 15β-alkoxy estrone derivatives and their cofactor-dependent inhibitory effect on 17β-HSD1.
    Herman BE; Kiss A; Wölfling J; Mernyák E; Szécsi M; Schneider G
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1271-1286. PubMed ID: 31307240
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis and biological evaluation of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitors based on a thieno[2,3-d]pyrimidin-4(3H)-one core.
    Lilienkampf A; Karkola S; Alho-Richmond S; Koskimies P; Johansson N; Huhtinen K; Vihko K; Wähälä K
    J Med Chem; 2009 Nov; 52(21):6660-71. PubMed ID: 19824648
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Towards the evaluation in an animal disease model: Fluorinated 17β-HSD1 inhibitors showing strong activity towards both the human and the rat enzyme.
    Abdelsamie AS; Bey E; Gargano EM; van Koppen CJ; Empting M; Frotscher M
    Eur J Med Chem; 2015 Oct; 103():56-68. PubMed ID: 26322835
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of estrogen-dependent diseases: Design, synthesis and profiling of a selective 17β-HSD1 inhibitor with sub-nanomolar IC
    Abdelsamie AS; van Koppen CJ; Bey E; Salah M; Börger C; Siebenbürger L; Laschke MW; Menger MD; Frotscher M
    Eur J Med Chem; 2017 Feb; 127():944-957. PubMed ID: 27852458
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relative involvement of three 17beta-hydroxysteroid dehydrogenases (types 1, 7 and 12) in the formation of estradiol in various breast cancer cell lines using selective inhibitors.
    Laplante Y; Rancourt C; Poirier D
    Mol Cell Endocrinol; 2009 Mar; 301(1-2):146-53. PubMed ID: 18812208
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chemical Synthesis and Biological Evaluation of 3-Substituted Estrone/Estradiol Derivatives as 17β-Hydroxysteroid Dehydrogenase Type 1 Inhibitors Acting via a Reverse Orientation of the Natural Substrate Estrone.
    Ngueta AD; Roy J; Maltais R; Poirier D
    Molecules; 2023 Jan; 28(2):. PubMed ID: 36677690
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitory activity and selectivity.
    Bey E; Marchais-Oberwinkler S; Negri M; Kruchten P; Oster A; Klein T; Spadaro A; Werth R; Frotscher M; Birk B; Hartmann RW
    J Med Chem; 2009 Nov; 52(21):6724-43. PubMed ID: 19831396
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of structural modifications at positions 13, 16 and 17 of 16β-(m-carbamoylbenzyl)-estradiol on 17β-hydroxysteroid dehydrogenase type 1 inhibition and estrogenic activity.
    Maltais R; Trottier A; Barbeau X; Lagüe P; Perreault M; Thériault JF; Lin SX; Poirier D
    J Steroid Biochem Mol Biol; 2016 Jul; 161():24-35. PubMed ID: 26519987
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of potential preclinical candidates with promising in vitro ADME profile for the inhibition of type 1 and type 2 17β-Hydroxysteroid dehydrogenases: Design, synthesis, and biological evaluation.
    Abdelsamie AS; Salah M; Siebenbürger L; Hamed MM; Börger C; van Koppen CJ; Frotscher M; Hartmann RW
    Eur J Med Chem; 2019 Sep; 178():93-107. PubMed ID: 31176098
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of fused 16β,17β-oxazinone-estradiol derivatives as a new family of non-estrogenic 17β-hydroxysteroid dehydrogenase type 1 inhibitors.
    Maltais R; Trottier A; Delhomme A; Barbeau X; Lagüe P; Poirier D
    Eur J Med Chem; 2015 Mar; 93():470-80. PubMed ID: 25728028
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis, biochemical evaluation and rationalisation of the inhibitory activity of a series of 4-hydroxyphenyl ketones as potential inhibitors of 17beta-hydroxysteroid dehydrogenase type 3 (17beta-HSD3).
    Lota RK; Dhanani S; Owen CP; Ahmed S
    Bioorg Med Chem Lett; 2006 Sep; 16(17):4519-22. PubMed ID: 16797984
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel estrone mimetics with high 17beta-HSD1 inhibitory activity.
    Oster A; Klein T; Werth R; Kruchten P; Bey E; Negri M; Marchais-Oberwinkler S; Frotscher M; Hartmann RW
    Bioorg Med Chem; 2010 May; 18(10):3494-505. PubMed ID: 20413314
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery of highly potent, nonsteroidal 17β-hydroxysteroid dehydrogenase type 1 inhibitors by virtual high-throughput screening.
    Starčević Š; Turk S; Brus B; Cesar J; Lanišnik Rižner T; Gobec S
    J Steroid Biochem Mol Biol; 2011 Nov; 127(3-5):255-61. PubMed ID: 21920439
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Computational investigation of the binding mode of bis(hydroxylphenyl)arenes in 17β-HSD1: molecular dynamics simulations, MM-PBSA free energy calculations, and molecular electrostatic potential maps.
    Negri M; Recanatini M; Hartmann RW
    J Comput Aided Mol Des; 2011 Sep; 25(9):795-811. PubMed ID: 21822722
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A new nonestrogenic steroidal inhibitor of 17β-hydroxysteroid dehydrogenase type I blocks the estrogen-dependent breast cancer tumor growth induced by estrone.
    Ayan D; Maltais R; Roy J; Poirier D
    Mol Cancer Ther; 2012 Oct; 11(10):2096-104. PubMed ID: 22914440
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.